Valeant Pharmaceuticals International Inc. surprised investors Tuesday and maintained its full-year guidance, setting a goal for the second half that will require the drugmaker to substantially raise its sales and profits.
As part of a planned turnaround, Valeant plans to sell assets that the company thinks will be worth about $8 billion, will renegotiate terms with lenders and will reorganize its business into three main segments as it tries to stabilize sales of several important but struggling products.
11:57 Qualcomm says Apple to stop paying royalties, cuts profit forecast15
23:59 Shares in Takata suspended after reported bankruptcy filing plan18
19:56 The Fate Of The Furious Will Be The 30th Movie To Make A Billion Dollars — See The Hit List HERE!21
10:18 Chevron to sell Bangladesh gas fields to Chinese co24